This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    10/09/19

    Role of microRNAs in chronic lymphocytic leukemia pathogenesis.

    MicroRNAs (miRNAs) are a group of small endogenous non-coding RNAs involved in many cancers and various cellular processes such as cellular growth, DNA methylation, apoptosis, and differentiation.

    • Source: Current Medicinal Chemistry
    Journals
    Journal
    30/04/19

    Venetoclax in the treatment of chronic lymphocytic leukemia

    Areas covered: This article reviews the chemical structure, mechanisms of action, pharmacokinetic, and the clinical applications of venetoclax in monotherapy and in combined treatment of CLL.

    • Source: Expert Opinion on Drug Metabolism & Toxicology
    Journals
    Journal
    01/11/19

    Chronic lymphocytic leukaemia: from genetics to treatment.

    Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5+CD23+ B cells in the peripheral blood...

    • Source: Nature Reviews Clinical Oncology
    Journals
    Journal
    01/02/19

    Brain invasion by chronic lymphocytic leukemia

    Brain invasion by chronic lymphocytic leukemia (CLL) is very rare, and only a handful of cases have been reported. We here report a case of 61-year-old woman who had been treated for CLL for 14 years presenting with a progressive...

    • Source: Neuropathology
    Journals
    Journal
    01/03/19

    Impact of CD39 expression on CD4+ T lymphocytes and 6q deletion on outcome of patients with chronic lymphocytic leukemia

    Objective/Background: Chronic lymphocytic leukemia is one of the commonest leukemias affecting adults. CD39 inhibits T-cell and Natural killer (NK) cell responses by hydrolyzing adenosine triphosphate and adenosine diphosphate...

    • Source: Hematology/Oncology and Stem Cell Therapy
    Journals
    Journal
    24/04/19

    Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...

    • Source: Blood
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/06/22

    NICE (UK)recommends venetoclax for treatment of chronic lymphocytic leukemia.

    The National Institute for Health and Care Excellence (NICE)(UK); Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic leukaemia (CLL) in adults

    Red and white blood cells within the body, representing blood cancers
    01/12/25

    Leukemia

    Latest news, insights, and guideline updates

    Blue test tubes arranged in a line, disappearing into the background
    News
    25/10/24

    Calquence approved in Japan to treat relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma)-AstraZeneca

    AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/11/19

    FDA approves Calquence to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma.- AstraZeneca.

    AstraZeneca announced that the FDA has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic...

    See more